{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RIF&page=3",
    "query": {
      "intervention": "RIF",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 187,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RIF&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RIF&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T21:32:08.002Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04312282",
      "title": "The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Tesetaxel",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Odonate Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2020-03-06",
      "completion_date": "2021-06-15",
      "has_results": false,
      "last_update_posted_date": "2021-07-28",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04312282"
    },
    {
      "nct_id": "NCT03624959",
      "title": "Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Gemfibrozil",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-06-20",
      "completion_date": "2018-08-10",
      "has_results": false,
      "last_update_posted_date": "2019-05-30",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03624959"
    },
    {
      "nct_id": "NCT02019875",
      "title": "CYP3A4 Activity and Mineral Homeostasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Vitamin D and Calcium Homeostasis"
      ],
      "interventions": [
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Clarithromycin",
          "type": "DRUG"
        },
        {
          "name": "Grapefruit Juice",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 92,
      "start_date": "2014-06",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2023-04-19",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019875"
    },
    {
      "nct_id": "NCT04029584",
      "title": "Drug-Drug Interaction Between Rifampin and Fluvastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Drug-drug Interaction"
      ],
      "interventions": [
        {
          "name": "rifampin IV",
          "type": "DRUG"
        },
        {
          "name": "Rifadin 300Mg Capsule",
          "type": "DRUG"
        },
        {
          "name": "Fluvastatin 20 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-04-25",
      "completion_date": "2020-04-25",
      "has_results": true,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04029584"
    },
    {
      "nct_id": "NCT07018635",
      "title": "A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "INCB161734",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2025-07-16",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07018635"
    },
    {
      "nct_id": "NCT03983239",
      "title": "Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Fedratinib",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2019-06-21",
      "completion_date": "2019-11-06",
      "has_results": false,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03983239"
    },
    {
      "nct_id": "NCT02500667",
      "title": "A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Interaction Potentiation"
      ],
      "interventions": [
        {
          "name": "N91115",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2015-06",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Lakewood, Colorado",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500667"
    },
    {
      "nct_id": "NCT01341184",
      "title": "TMC207 +/- Rifabutin/Rifampin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifabutin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "TMC207",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 33,
      "start_date": "2011-10-21",
      "completion_date": "2012-05-23",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01341184"
    },
    {
      "nct_id": "NCT02252198",
      "title": "Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Epistem Genedrive® and MolBio Truenat™",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2014-02",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252198"
    },
    {
      "nct_id": "NCT06363630",
      "title": "A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Golcadomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 35,
      "start_date": "2024-04-23",
      "completion_date": "2024-08-29",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-10-26T21:32:08.002Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Lenexa, Kansas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06363630"
    }
  ]
}